Success Metrics

Clinical Success Rate
100.0%

Based on 6 completed trials

Completion Rate
100%(6/6)
Active Trials
2(8%)
Results Posted
17%(1 trials)

Phase Distribution

Ph phase_2
5
20%
Ph not_applicable
3
12%
Ph phase_1
1
4%
Ph phase_3
10
40%
Ph phase_4
5
20%

Phase Distribution

1

Early Stage

5

Mid Stage

15

Late Stage

Phase Distribution24 total trials
Phase 1Safety & dosage
1(4.2%)
Phase 2Efficacy & side effects
5(20.8%)
Phase 3Large-scale testing
10(41.7%)
Phase 4Post-market surveillance
5(20.8%)
N/ANon-phased studies
3(12.5%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

85.7%

6 of 7 finished

Non-Completion Rate

14.3%

1 ended early

Currently Active

2

trials recruiting

Total Trials

25

all time

Status Distribution
Active(4)
Completed(6)
Terminated(1)
Other(14)

Detailed Status

unknown14
Completed6
Recruiting2
Withdrawn1
Enrolling by invitation1
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
25
Active
2
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (4.2%)
Phase 25 (20.8%)
Phase 310 (41.7%)
Phase 45 (20.8%)
N/A3 (12.5%)

Trials by Status

unknown1456%
completed624%
withdrawn14%
enrolling_by_invitation14%
not_yet_recruiting14%
recruiting28%

Recent Activity

Clinical Trials (25)

Showing 20 of 25 trialsScroll for more
NCT06769685

TPO Combined With TPORA for Solid Tumors Effectiveness of cTit Above Degree II

Enrolling By Invitation
NCT05583838Phase 4

A Randomized Trial Comparing Optimized rhTPO Treatment With Eltrombopag Treatment in Pre-treated ITP Pts

Completed
NCT05944809Phase 2

The Effect of Prophylactic TPO Combined with BMS-IMRT to Esophageal Cancer Patients

Completed
NCT06525948Phase 4

Efficacy and Safety of rhTPO in Combination With Cyclosporine Versus Cyclosporine Alone in the Treatment of TD-NSAA

Not Yet Recruiting
NCT02707497Phase 2

The Effect of REcombinant Human Thrombopoietin (rhTPO) on Sepsis Patients With aCUte Severe thrombocytopEnia

Recruiting
NCT05411705Phase 4

Efficacy and Safety of rhTPO's Prophylactic Treatment of CTIT in Patients With High Risk of Cardiac Injury

Recruiting
NCT03515096Phase 3

Eltrombopag vs. rhTPO to Increase Platelet Level After HSCT

Completed
NCT05382390Phase 3

Dual Growth Factor (rhTPO + G-CSF) and Chemotherapy Combination Regimen in Acute Myeloid Leukemia: Study Protocol for a Randomized Controlled Trial

Unknown
NCT05328804Phase 3

Herombopag + rhTPO in Severe Immune Thrombocytopenia

Unknown
NCT05258799Not Applicable

Dual Growth Factor (rhTPO + G-CSF) and Chemotherapy Combination Regimen for Elderly Patients With Acute Myeloid Leukemia: A Phase II Single-Arm Multicenter Study

Unknown
NCT04518878Phase 1

Fixed Low-dose Eltrombopag and rhTPO for Immune Thrombocytopenia (FLOWER)

Unknown
NCT04516837Phase 2

Eltrombopag Plus rhTPO Versus Eltrombopag for ITP During the COVID-19 Pandemic (ELABORATE-19)

Unknown
NCT02487563Phase 3

Prospective Study of Patients With Thrombocytopenia Following HSCT

Completed
NCT02391272Phase 3

A Multicenter Study on Recombinant Human Thrombopoietin in Management of ITP in Pregnancy

Completed
NCT04168138Not Applicable

D-CTAG in the Treatment of Newly Diagnosed Acute Myeloid Leukemia in Elderly Patients

Unknown
NCT03771378Phase 4

Efficacy and Safety of rhTPO and Eltrombopag in Patients With Primary Immune Thrombocytopenia (ITP)

Unknown
NCT03823079Phase 2

Comparison of Interleukin-11 and rhTPO for Recurrent Colorectal Cancer Patients With Thrombocytopenia

Unknown
NCT03633019Phase 4

High-dose Use of rhTPO in CIT Patients

Unknown
NCT00283582Phase 3

Trial of Primary Prophylaxis With rhTPO Administered to Patients With High Risk Sarcoma Receiving Intensive Chemotherapy

Completed
NCT02572596Not Applicable

Comparing Intermediate-dose CTX+ G-CSF Plus or Not rhTPO for PB CD34+ Cells Mobilization in MM Patients

Unknown

Drug Details

Intervention Type
DRUG
Total Trials
25